Skip to main content
OpenTrials
Completed

NCT Number: NCT04740658

Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents

The COVID epidemic has shown very high mortality among older people, especially among poly-morbid and dependent subjects. In addition to the classic risk factors of age, dependence and associated co-morbidities, community life exposes to specific increased risks in the event of this easily inter human transmissible viral epidemic. In France, according to the Direction of research, studies, evaluation and statistics (DREES) data (Ehpa study, 2015) more than 600,000 elderly people currently live in nursing homes (NH). Since March 28, a national guidance for monitoring the COVID epidemic in NH has just been set up. In France, 14 178 of the 29 319 COVID deaths (48.35%) by June 10th 2020 occurred among NHs residents. Work to consolidate these data is underway, suggesting a much heavier balance sheet. Faced to this threat, in addition to practical recommendations (barrier protection gestures), strict instructions were also announced to all NH to keep their residents safe from COVID : restricting all visitors, all volunteers and nonessential personnel, and more recently, confining residents in their room in case of incident case of COVID in the NH. Organizational factors of NH such as the prevention strategies deployed before and during the epidemic (pneumococcal vaccination, restricting group activities), as well as NH internal resources (equipment, nursing staff) and health resources in the NH environment (hospital partnerships, support devices, telemedicine) lead to heterogeneous situations and could influence the death rates of residents. On the other hand, social isolation can also precipitate the decline of fragile residents. Beyond the immediate and directly risks linked to COVID-19, the present hypothesize that the organizational measures (guidance and recommendations) put in place can have, during and at a distance from the outbreak, beneficial effects but also deleterious effects depending on the severity of the outbreak of a geographic area. More precisely, the hypothesis is that strong and well-followed recommendations at the time of the epidemic were associated with a reduction in the risk of total death in particular of deaths related to COVID in the zones most affected by the epidemic but also that strong and well-followed recommendations were associated with an increased risk of total death, in particular of deaths unrelated to COVID in the areas least affected by the epidemic.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Toulouse - Gérontopôle

Toulouse, 31059, France

About this study

The PIANO COVID-19 study is an observational, ambidirectional multicenter cohort study. The study will compare the death rates (COVID and non-COVID) in NHs according to the application of the general and specific recommendations of the region by the NH teams, taking into account the COVID infection rate in the NH department, the transfer capacities to hospitals, the medicalization of NH and the general characteristics of residents of NH. These parameters having been fluctuating over time, the analysis will also take into account the period considered.

3 sources of data will be used :

  • Questionnaire: The NH team leaders will be asked to report variable related to the implementation of the recommendation/guidance by the nursing home staff, the general characteristics of the residents, and characteristics of the NH, and the monthly rate of death from January to December 2020.

A score will be built in regard to the implementation of the recommendation/guidance from the nursing home staff.

  • Data related to the recommendations/guidance of the 13 regions of France (general guidance such as barriers measures and specificity guidance), the COVID infection rate in each NH department, the transfer capacities to hospitals and emergency department, will be collected by the PIANO COVID-19 research team.

For this purpose, referent teams for the COVID-19 outbreak of the each Regional Health Agency (RHA) of the 13 regions of France are contacted in order to recover the recommendation documents having been sent to the NHs.

  • Official national data related to the COVID infection rate in the NH administrative region, and transfer capacities to hospitals, will be collected from open access website of the "Santé Publique France" website or other official websites currently providing these data. These data are updated on a daily basis for all administrative region of France and have been registered from the beginning of the outbreak.
  • Qualitative study: To improve the understanding of the effects of the recommendations/guidance on resident's health, we will carry out a qualitative study with the NH staff of 20 public and private NH (half clusters NH for COVID-19 and half NH saved from COVID-19). Onsite semi-structured interviews will be conducted with the NH staff to better understand the subjective assessment of healthcare professional on the impact of the recommendations/guidance on the residents' health status. The main questions to which the interviews with the nurses and the nursing assistants will answer, will relate to the functional decline, the appetite and the nutritional status, the mood, the evolution of the cognitive capacities, their psycho-behavioral disturbances and their quality of life during the epidemic period. This qualitative survey will be carried out among NHs having been strongly impacted by the epidemic (NHs cluster with more than 20 deaths) and NHs having not at all been affected by the epidemic (no case of COVID-19 among residents or health care professional). The qualitative study will involve NHs located in very variable geographical regions in regards to the outbreak.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Within each NH, all NH residents living in the NH the 1st of January 2020 will be included.

Exclusion criteria

  • NHs or Long Term Care Facilities (LTCFs) that refuse to participate.
  • NHs that are not voluntary or not located in the regions and NHs that do not have a coordinating doctor .
  • Within each NH, all NH residents not living in the NH or LTCFs the 1st of January 2020 will be not be included.

Treatment and study plan

No intervention

Other

There is no intervention

Primary outcomes

  1. Death occurrence within one year of follow up

    Time frame: from January 2020 to December 2020

    • Primary criteria is death occurrence within one year of follow up: death rates will be recorded.
    • Level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection will be score 14 days before the peak wave of the outbreak in the geographic area of each NH.

Secondary outcomes

  1. deaths related to COVID during the one-year follow-up

    Time frame: from January 2020 to December 2020

    The secondary objective N°1 is to compare the rate of death related to confirmed or suspected COVID cases in NH with a high level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection and NH with a low level of implementation of the recommendation/guidance to prevent and control COVID-19 NH.

Other outcomes

  1. deaths not related to COVID during the one-year follow-up

    Time frame: from January 2020 to December 2020

    The secondary objective N°2 is to compare the rate of death not related to COVID cases in NH with a high level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection and NH with a low level of implementation of the recommendation/guidance to prevent and control COVID-19 NH.

  2. evaluate the economic impact of the implementation of prevention measures

    Time frame: 6 and 12 months before and after the implementation of the preventive measures

    This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.

    • Direct medical and non-medical costs 6 and 12 months before and after the high or low level implementation of recommendations to prevent and control COVID-19, using the Mandatory National Health Insurance database.

  3. Health economic study: evaluate Direct medical and non-medical costs

    Time frame: 6 and 12 months before and after the implementation of the preventive measures

    This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.

    • Direct medical and non-medical costs rate to assess the cost-effectiveness of high-level implementation of recommendation to prevent and control COVID-19.

  4. Health economic study: evaluate the mortality rate

    Time frame: 6 and 12 months before and after the implementation of the preventive measures

    This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.

    • Mortality rate to assess the cost-effectiveness of high-level implementation of recommendation to prevent and control COVID-19.

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Official study title

Effect of Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents During and After the Epidemic Period

Acronym: PIANO-COVID-19

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Feb 5, 2021
Registry last updated
Dec 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.